Methods for characterizing agonists and partial agonists of target molecules
View Patent ↗In one aspect, the present invention provides methods of determining whether an agent is more like a partial agonist of a target molecule than a full agonist of the same target molecule. In another aspect, the present invention provides methods to select a candidate compound that may reduce blood plasma glucose concentration in a mammal. Populations of genes are provided that are useful in the practice of the present invention.
1. A method of determining whether an agent is more like a partial agonist of a target molecule than a full agonist of the same target molecule, the method comprising the steps of:
(a) comparing the magnitude of gene expression of a first population of genes, in cells of a cell type, in response to an agent to the magnitude of gene expression of the first population of genes, in cells of the cell type, in response to a full agonist of a target molecule, to produce a first comparison result, wherein the first population of genes is an efficacy-related population of genes that consists of a population of 29 genes that each hybridize under stringent conditions to a different member of the group of nucleic acid molecules consisting of SEQ ID NOS:1-29, and wherein the first comparison result is represented by a first numerical value;
(b) comparing the magnitude of gene expression of a second population of genes, in cells of the cell type, in response to the agent to the magnitude of gene expression of the second population of genes, in cells of the cell type, in response to the full agonist of the target molecule, to produce a second comparison result, wherein the second population of genes is a toxicity-related population of genes that consists of a population of 11 genes that each hybridize under stringent conditions to a different member of the group of nucleic acid molecules consisting of SEQ ID NOS:30-40, and wherein the second comparison result is represented by a second numerical value; and
(c) using the first numerical value and the second numerical value to determine whether the agent is more like a partial agonist of the target molecule than the full agonist of the target molecule, wherein any part of step (a) can occur before, during, or after any part of step (b),
wherein steps (a), (b), and (c) are performed by a suitably programmed computer.
2. The method of claim 1 wherein gene expression is measured by measuring RNA expression.
3. The method of claim 1 wherein gene expression is measured by measuring mRNA expression.
4. The method of claim 1 wherein gene expression is measured by measuring protein expression.
5. The method of claim 1 wherein chi-square analysis is used to compare the magnitudes of expression of the gene populations to obtain the first and second numerical values.
6. The method of claim 1 wherein the determination is made that the agent is more like the partial agonist than the full agonist if the comparison result for the first population of genes is significantly greater than the comparison result for the second population of genes.
7. The method of claim 1 wherein the first and second numerical values are compared on a comparison plot to determine whether the agent is more like the partial agonist than the full agonist of the target molecule.
8. The method of claim 1 wherein the ratio of the first numerical value to the second numerical value is used to determine whether the agent is more like the partial agonist than the full agonist of the target molecule.
9. The method of claim 8 wherein the determination is made that the agent is more like the partial agonist than the full agonist if the ratio of the first numerical value to the second numerical value is greater than a selected value.
10. The method of claim 8 wherein the determination is made that the agent is more like the partial agonist than the full agonist if the ratio of the first numerical value to the second numerical value is greater than one.
11. The method of claim 1 wherein the determination is made that the agent is more like the partial agonist than the full agonist if the comparison result for the efficacy-related population of genes is significantly greater than the comparison result for the toxicity-related population of genes.
12. The method of claim 1 wherein a ratio of the first numerical value to the second numerical value is calculated, and the determination is made that the agent is more like the partial agonist than the full agonist if the ratio is greater than one.
13. The method of claim 1 wherein a ratio of the second numerical value to the first numerical value is calculated, and the determination is made that the agent is more like the partial agonist than the full agonist if the ratio is less than one.
14. The method of claim 1 wherein the target molecule is a PPARγ molecule.
15. The method of claim 14 wherein the determination is made that the agent is more like a partial PPARγ agonist than a full PPARγ agonist if the comparison result for the efficacy-related population of genes is significantly greater than the comparison result for the toxicity-related population of genes.
16. The method of claim 1 further comprising the step of ranking a multiplicity of agents to form a rank of agents, wherein the position of an agent in the rank indicates the level of similarity of the agent to a partial agonist of the target molecule.
17. The method of claim 1 wherein the cells are contacted with a non-saturating amount of the agent before the magnitude of gene expression of the first population of genes and the magnitude of gene expression of the second population of genes are measured.
18. The method of claim 1 wherein the cells are contacted with a saturating amount of the agent before the magnitude of gene expression of the first population of genes and the magnitude of gene expression of the second population of genes are measured.
19. A method of determining whether an agent is more like a partial agonist of a PPARγ molecule than a full agonist of the PPARγ molecule, the method comprising the steps of:
(a) comparing the magnitude of gene expression, in cells of a cell type, of a first population of 29 genes, that each hybridize under stringent conditions to a different member of the group of nucleic acid molecules consisting of SEQ ID NOS:1-29, in response to an agent, to the magnitude of gene expression, in cells of the cell type, of the first population of genes in response to a full agonist of a PPARγ molecule, to produce a first comparison result, wherein the first comparison result is represented by a first numerical value;
(b) comparing the magnitude of gene expression, in cells of the cell type, of a second population of 11 genes, that each hybridize under stringent conditions to a different member of the group of nucleic acid molecules consisting of SEQ ID NOS:30-40, in response to the agent, to the magnitude of gene expression of the second population of genes, in cells of the cell type, in response to the full agonist of the PPARγ molecule, to produce a second comparison result, wherein the second comparison result is represented by a second numerical value; and
(c) using the first numerical value and the second numerical value to determine whether the agent is more like a partial agonist of the PPARγ molecule than the full agonist of the PPARγ molecule, wherein any part of step (a) can occur before, during, or after any part of step (b),
wherein steps (a), (b), and (c) are performed by a suitably programmed computer.